Clinical Report: Assessment of Safety for Subcutaneous Versus Intravenous Infliximab
Overview
Revise to specify the types of adverse events analyzed and their clinical relevance.
Background
Inflammatory Bowel Disease (IBD) significantly impacts patients' quality of life and is associated with increased complications. Infliximab, a key therapeutic agent for moderate-to-severe IBD, is administered either intravenously or subcutaneously. Understanding the safety profiles of these administration routes is crucial for optimizing patient care and minimizing adverse reactions.
Data Highlights
Administration Route
Adverse Events
Median Onset Time (days)
Intravenous
5,144
436.5
Subcutaneous
1,084
376
Key Findings
178,925 adverse reaction reports associated with infliximab were identified.
Infection-related adverse reactions were common for both administration routes.
Infusion-related reactions were more frequently reported with intravenous administration.
Delayed hypersensitivity reactions were more prominently reported with subcutaneous administration.
The median onset time for AEs was shorter for subcutaneous (376 days) compared to intravenous (436.5 days) administration.
Clinical Implications
Clinicians should weigh the differences in adverse event profiles and onset times when choosing between intravenous and subcutaneous infliximab for IBD treatment. This knowledge can help tailor therapy to individual patient needs, balancing efficacy with safety.
Conclusion
The study underscores the importance of understanding the safety profiles of infliximab administration routes, which can guide clinicians in optimizing treatment strategies for patients with IBD.
